Copertina

Letter: Early real‐world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Maryam Alahmad, Mohammed Nabil Quraishi, Shaima Wasim Khan, Nadeen Mamon Omar, Talha A. Malik
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid‐free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease
di: Stefan Schreiber, et al.
Pubblicazione: (2024)

Letter: Crohn's Disease With Latent Tuberculosis Infection or Intestinal Tuberculosis: Rapid Discrimination by Targeted Next‐Generation Sequencing
di: Maryam Irshad, et al.
Pubblicazione: (2025)

Letter: Methodological Caveats in Zhang et al.–Gut Microbiota and Metabolism in Cirrhotic Portal Hypertension
di: Muhammad Talha Ghaffar
Pubblicazione: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
di: Tamar Schildkraut, et al.
Pubblicazione: (2024)

Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns
di: Kuan‐Ju Lin, et al.
Pubblicazione: (2025)

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
di: Zhidong Zhou, et al.
Pubblicazione: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
di: Virginia Solitano, et al.
Pubblicazione: (2024)

Letter: The Simple Endoscopic Score for Predicting Crohn's Disease Progression—Not as Simple as It Sounds
di: Ziheng Calvin Xu, et al.
Pubblicazione: (2025)

Letter: Putting Crohn's Risk Prediction to Work in Perianal Fistula—Calibration, Thresholds, and Transport
di: Emmanuel Pio Pastore
Pubblicazione: (2025)

Letter: Gut microbiota—An overlooked therapeutic target in the prevention of post‐operative recurrence of Crohn's disease
di: D. Bogatic, et al.
Pubblicazione: (2024)

Letter: ‘Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study’
di: Matthias Kelm, et al.
Pubblicazione: (2025)

Letter: Extreme diagnostic delay due to misdiagnosis of gastrointestinal tuberculosis later diagnosed as postoperative Crohn's disease
di: Abhirup Chatterjee, et al.
Pubblicazione: (2024)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Considerations for Outcome Measurement and Clinical Interpretation
di: Dingsheng Liu, et al.
Pubblicazione: (2025)

Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease
di: Jiacheng Li
Pubblicazione: (2026)

Letter: The Prognostic Role of IGF‐1 in Chronic Liver Disease
di: Muhammad Osama, et al.
Pubblicazione: (2024)

Letter: Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study: Authors' Reply
di: Nathan Grellier, et al.
Pubblicazione: (2025)

Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease. Authors' Reply
di: José Luis Rueda García, et al.
Pubblicazione: (2026)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Critical Considerations for Outcome Measurement and Clinical Interpretation. Authors' Reply
di: Jeffrey D. McCurdy, et al.
Pubblicazione: (2025)

Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises the Importance of Appropriate Patient Selection and Centre Expertise
di: Weilun Gao, et al.
Pubblicazione: (2024)

Letter: Allostatic load—A potential key in the development of inflammatory bowel disease
di: Maryam Kharal, et al.
Pubblicazione: (2024)

Editorial: Upadacitinib in Perianal Crohn's Disease
di: Manjeet Kumar Goyal, et al.
Pubblicazione: (2026)

Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise—Authors' Reply
di: Péter Bacsur, et al.
Pubblicazione: (2024)

Efficacy and safety of filgotinib for ulcerative colitis: A real‐world multicenter retrospective study in Japan
di: Shintaro Akiyama, et al.
Pubblicazione: (2024)

Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients
di: Jian Wang, et al.
Pubblicazione: (2024)

Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed
di: Haibo Jing, et al.
Pubblicazione: (2024)

Systematic Review of Published Guidelines: Recommendations for Exams Under Anaesthesia, Seton Insertion and Timing of Seton Removal for Perianal and Rectovaginal Fistulising Crohn's Disease
di: Edgard Medawar, et al.
Pubblicazione: (2026)

Performance of bowel preparation quality scales in patients with Crohn's disease
di: Virginia Solitano, et al.
Pubblicazione: (2024)

Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
di: Antoine Meyer, et al.
Pubblicazione: (2025)

Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed. Authors' reply
di: Andrea Martini, et al.
Pubblicazione: (2024)

Editorial: Upadacitinib—A Promising Induction Agent for Paediatric Crohn's Disease?
di: Vincenzo Stranges, et al.
Pubblicazione: (2025)

Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras
di: Daniel Tassone, et al.
Pubblicazione: (2024)

Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply
di: Jeffrey D McCurdy, et al.
Pubblicazione: (2025)

Editorial: Examining Perianal Fistulising Crohn's Disease Through the Lens of Wound Repair
di: Tim Eglinton
Pubblicazione: (2025)

Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study
di: Shlomi Cohen, et al.
Pubblicazione: (2025)

Editorial: Real‐World Evidence of Upadacitinib—An Effective Induction Therapy for Crohn's Disease?
di: C. Ramos‐Belinchon, et al.
Pubblicazione: (2025)

Editorial: Mesenchymal Stem Cell Therapy for Perianal Fistulising Crohn's Disease—Effective or Hype?
di: Jeffrey D McCurdy, et al.
Pubblicazione: (2024)

Editorial: Endoscopic Activity is an Essential Tool for Patients' Management, Even in Mild Crohn's Disease
di: Marco Mendolaro, et al.
Pubblicazione: (2025)

Editorial: Infliximab induction therapy in pediatric Crohn's disease—A cost‐effective strategy?
di: Neil Chanchlani, et al.
Pubblicazione: (2024)

Editorial: Beyond Resection—Rethinking Postoperative Management in Colonic Crohn's Disease. Authors' Reply
di: José Luis Rueda García, et al.
Pubblicazione: (2026)

Systematic review: Defining, diagnosing and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound
di: Cathy Lu, et al.
Pubblicazione: (2024)